Skip to main content

RheumNow Podcast โ€“ Coconspirators: RA and Lung Disease

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

  1. BC, Canada study of Lupus mortality: 6,092 SLE pts followed for 17 yrs, there were 451 deaths. Compared to population, all cause mortality was nearly 2 fold higher (HR 1.85; 1.66-2.06); excess deaths from renal (HR 3.04), INFX (2.74) & CVD (2.05) https://bit.ly/2PeVP7i
  2. Diary study of 79 FM, 86 RA, 33 w/ both FM/RA shows that compared to RA, pts with FM have worse daily well-being, negative affect, more isolation, inability to complete plans. FM had more perceived stigma and lower well-being. https://bit.ly/2QeOW6c
  3. When DOACs (Xarelto, Eliquis) used for Afib or VTE, concomitant aspirin also given (without indication) in 34%. There was no additional anti-thrombotic effect, PLUS ASA use adds 20% increased risk of non-major bleeding. Registry cohort study of 3280 pts. https://t.co/6vDw8HfDZX
  4. 37 RA, 28 PsA & 20 AS pts in remission/LDA x 6 mos enrolled in DMARD spacing. Joint flares seen in 13.5% RA, 21.4% PsA & 20% axSpA pts but 5 more PsA patients had skin flare. PsA had lower persistence 61% (vs RA 87% & 80% AS) due to skin flares https://t.co/d1rMLTXSQs
  5. 55 pts w/ Multi-joint osteonecrosis (>2 jts).(SLE 29%, ALL 11%, HIV 9%, EtOH 4%). Mean cumulative steroid dose >30 g over 5 yrs. Predictors of MJON was cumulative oral steroid dose (3.2% incr per 1000 mg. MJON risk incr 12 fold w/ 2nd risk factor. https://t.co/dqTPh2PV8V
  6. Study of 207 Pediatric pts treated w/ Rituxan (for Rheum, Cancer, CNS, Renal dz) and 40% developed hypogammaglobulinemia post-RTX; hypo-IgG Pre-RTX 28.7% to Post RTX 42.6%, p=0.009; low IgG levels had higher risk of serious infx (OR 2.3) https://t.co/b91rPYgVV2
  7. Broadalumab Efficacy in Axial Spondyloarthritis Broadalumab, an anti-interleukin-17 receptor A monoclonal antibody, is FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axSpA. https://t.co/V0zKbFMgy7
  8. Sonelokimab is a novel trivalent nanobody aimed at IL-17A & IL-17F; tested at multiple doses vs Placebo or secukinumab in 383 plaque psoriasis pts: SON at doses 60-120 mg had efficacy similar to SEC; but SON had more Candida infx (17ยท4% vs 1.9% SEC) https://bit.ly/3vdysdq
  9. Randomized trial of 206 adults with knee OA found that a web-based exercise intervention supported by text messaging improved knee pain and function at 24 weeks vs web-based information alone. (MCID pain 72.1% vs 42%) https://t.co/h5UaedS4Zm
  10. Not in the US, but biosimilar infliximab (CT-P13) is being used subcutaneously in the EU and Canada. Analysis of 2 RCTs shows (compared to IV inflectra or remicade) SC CT-P13 greater DAS28-CRP, CDAI and SDAI response rates. https://t.co/prSVJ0BIdd
  11. Dual seropositivity with RF/ACPA autoantibody higher titers were strongly associated with prevalent RA-ILD (OR 2.90; developed in 3.7%). ILD more likely with high titer RF (HR 3.4) than high titer CCP (HR 1.9). https://t.co/ebvJjatQSw
  12. Increased Risk of COPD in ACPA+ Pre-RA Patients 
  13. Increased Methotrexate Liver Disease in Psoriasis 

Join The Discussion

Dr M Nazibur Rahman

| Apr 23, 2021 2:07 pm

excellent

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has received compensation as an advisor or consultant on this subject